Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2018 Oct 18

PMID 30327963

Citations 12

Authors

Alexander L Nguyen

Haesuk Park

Pauline Nguyen

Edward Sheen

Yoona A Kim

Mindie H Nguyen

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is the fastest-growing chronic liver disease. However, little is known about NAFLD inpatient resource utilization and clinical outcomes.

Aims: The aim of this study was to quantify inpatient NAFLD encounters using patient-level data over time.

Methods: This was a retrospective analysis of de-identified data for NAFLD patients from the California Patient Discharge Database from 2006 to 2013. NAFLD patients were identified by ICD9 codes 571.40, 571.41, 571.49, 571.8, and 571.9.

Results: NAFLD patients (n = 91,558) were predominantly female (60%), 45-65 years old (44%), and white (53%). Inpatient encounters increased from 8153 in 2006 to 16,457 in 2013 and were associated with a 207% increase in charges ($686 million in 2006 to $1.42 billion in 2013) and average increase in charges of 9.8% per year adjusting for inflation. Comorbidities (obesity, diabetes, hyperlipidemia, cardiovascular disease, other cancer, and renal disease) increased significantly over time (all P < 0.05). From 2006 to 2011, there were 11,463 deaths (1849 for liver-related hospitalizations) (mean follow-up 4.00 ± 2.13 years). The most significant predictors of death were age > 75 (aHR 3.9, P < 0.0001), male gender (aHR 1.10, P < 0.0001), white race (aHR 1.2, P < 0.0001), decompensated cirrhosis (aHR 2.1, P < 0.0001), and cancer other than HCC (aHR 3.2, P < 0.0001). Within the liver-related hospitalization cohort, mortality predictors were similar, except for Hispanic race (aHR 0.92, P < 0.0096) and renal disease (aHR 1.50, P < 0.0001).

Conclusions: The number of NAFLD inpatient encounters increased significantly from 2006 to 2013, as did the inflation-adjusted inpatient charges. The most significant predictors of death were non-liver cancers (HR 3.11, P < 0.0001, CI 3.06-3.16) and age > 75 years (HR 3.94, P < 0.0001, HR 3.86-4.03).

Citing Articles

Status and factors influencing health-related quality of life in patients with non-alcoholic fatty liver disease in Hangzhou: a cross-sectional study.

Lv K, Zhou R, Gu Y, Kong T, Chen Y, Shao Y BMJ Open. 2025; 15(3):e088357.

PMID: 40044211 PMC: 11883542. DOI: 10.1136/bmjopen-2024-088357.

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.

Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y BMC Med. 2024; 22(1):101.

PMID: 38448943 PMC: 10919055. DOI: 10.1186/s12916-024-03315-0.

Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action.

Younossi Z, Henry L Diabetes Spectr. 2024; 37(1):9-19.

PMID: 38385101 PMC: 10877219. DOI: 10.2337/dsi23-0010.

Estimating the cost of illness of non-alcoholic fatty liver disease in Bangladesh.

Alam S, Islam Alin M, Begum F, Fahim S, Tasnim Z, Alam M JGH Open. 2023; 7(9):629-635.

PMID: 37744705 PMC: 10517439. DOI: 10.1002/jgh3.12960.

Lifestyle interventions in nonalcoholic fatty liver disease.

Younossi Z, Zelber-Sagi S, Henry L, Gerber L Nat Rev Gastroenterol Hepatol. 2023; 20(11):708-722.

PMID: 37402873 DOI: 10.1038/s41575-023-00800-4.

References

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Mahady S, George J . Predicting the future burden of NAFLD and NASH. J Hepatol. 2018; 69(4):774-775. DOI: 10.1016/j.jhep.2018.06.025. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Udompap P, Kim D, Kim W . Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol. 2015; 13(12):2031-41. PMC: 4618163. DOI: 10.1016/j.cgh.2015.08.015. View

Lazo M, Hernaez R, Eberhardt M, Bonekamp S, Kamel I, Guallar E . Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1):38-45. PMC: 3698993. DOI: 10.1093/aje/kws448. View

Cholankeril G, Wong R, Hu M, Perumpail R, Yoo E, Puri P . Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017; 62(10):2915-2922. DOI: 10.1007/s10620-017-4684-x. View

Le M, Devaki P, Ha N, Won Jun D, Te H, Cheung R . Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017; 12(3):e0173499. PMC: 5367688. DOI: 10.1371/journal.pone.0173499. View

Estes C, Razavi H, Loomba R, Younossi Z, Sanyal A . Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017; 67(1):123-133. PMC: 5767767. DOI: 10.1002/hep.29466. View

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. DOI: 10.1002/hep.25762. View

10.

Young K, Aguilar M, Gish R, Younossi Z, Saab S, Bhuket T . Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. Liver Transpl. 2016; 22(10):1356-66. DOI: 10.1002/lt.24507. View

11.

Mantovani A, Zaza G, Byrne C, Lonardo A, Zoppini G, Bonora E . Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2017; 79:64-76. DOI: 10.1016/j.metabol.2017.11.003. View

12.

Koebnick C, Getahun D, Reynolds K, Coleman K, Porter A, Lawrence J . Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. J Pediatr Gastroenterol Nutr. 2009; 48(5):597-603. DOI: 10.1097/MPG.0b013e318192d224. View

13.

Kim W, Brown Jr R, Terrault N, El-Serag H . Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002; 36(1):227-42. DOI: 10.1053/jhep.2002.34734. View

14.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

15.

Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R . Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015; 21(10):645-662. DOI: 10.1016/j.molmed.2015.08.005. View

16.

Hsiang J, Bai W, Raos Z, Stableforth W, Upton A, Selvaratnam S . Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Intern Med J. 2014; 45(2):160-9. DOI: 10.1111/imj.12624. View

17.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

18.

Jun T, Yeh M, Yang J, Chen V, Nguyen P, Giama N . More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int. 2017; 38(5):895-902. DOI: 10.1111/liv.13613. View

19.

Younossi Z, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A . Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2014; 49(3):222-7. DOI: 10.1097/MCG.0000000000000071. View